


PHARMACEUTICAL 2020

Kura Oncology Inc. Rank 38 of 358







PHARMACEUTICAL 2020



Kura Oncology Inc. Rank 38 of 358

The relative strengths and weaknesses of Kura Oncology Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Kura Oncology Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 113% points. The greatest weakness of Kura Oncology Inc. is the variable Other Revenues, reducing the Economic Capital Ratio by 19% points.

The company's Economic Capital Ratio, given in the ranking table, is 236%, being 200% points above the market average of 36%.

Input Variable	Value in 1000 USD
Assets, Current	239,603
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	15,564
Liabilities, Non-Current	7,627
Other Assets	2,325
Other Compr. Net Income	462
Other Expenses	0
Other Liabilities	0
Other Net Income	4,339
Other Revenues	0
Property and Equipment	44
Research and Development	47,826
Selling, General and Administrative Expense	19,653

Output Variable	Value in 1000 USD
Assets	241,972
Liabilities	23,191
Expenses	67,479
Revenues	0
Stockholders Equity	218,781
Net Income	-63,140
Comprehensive Net Income	-62,909
Economic Capital Ratio	236%

